Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1850-1857

  Zhu, Bo ^a   Chen, Zhengtang ^a   Cheng, Xiaoming ^a   Lin, Zhihua ^b   Guo, Jianxiu ^a   Jia, Zhengcai ^a   Zou, Liyun ^a   Wang, Zhixin ^a   Hu, Yide ^a   Wang, Dongling ^a   Wu, Yuzhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; MESSENGER RNA; SYNTHETIC PEPTIDE; TAXOL RESISTANT ASSOCIATED ANTIGEN; TRAG 3 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; MELANOMA; MOLECULAR MODEL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0038666258     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Jager, D., Jager, E., and Knuth, A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. (Lond.), 54: 669-674, 2001.
2. Chiriva-Internati, M., Wang, Z., and Salati, E. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood, 100: 961-965, 2002.
3. Van Pel, A., van der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethe, B., van den Eynde, B., Uyttenhove, C., Renauld, J. C., and Boon, T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev., 145: 229-250, 1995.
4. Zendman, A. J., Van Kraats, A. A., Weidle, U. H., Ruiter, D. J., and Van Muijen, G. N. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. Int. J. Cancer, 99. 361-369, 2002.
5. Haffner, A. C., Tassis, A., Zepter, K., Storz, M., Tureci, O., Burg, G., and Nestle, F. O. Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int. J. Cancer, 97: 668-670, 2002.
6. Weynants, P., Lethe, B., Brasseur, F., Marchand, M., and Boon, T. Expression of mage genes by non-small-cell lung carcinomas. Int. J. Cancer, 56: 826-829, 1994.
7. Salgaller, M. L., Weber, J. S., Koenig, S., Yannelli, J. R., and Rosenberg, S. A. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide: Cancer Immunol. Immunother., 39: 105-116, 1994.
8. Sadanaga, N., Nagashima, H., Mashino, K., Tahara, K., Yamaguchi, H., Ohta, M., Fujie, T., Tanaka, F., Inoue, H., Takesako, K., Akiyoshi, T., and Mori, M. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res., 7: 2277-2284, 2001.
9. Jager, E., Chen, Y. T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J., and Knuth, A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med., 187: 265-270, 1998.
10. Nishiyama, T., Tachibana, M., Horiguchi, Y., Nakamura, K., Ikeda, Y., Takesako, K., and Murai, M. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin. Cancer Res., 7: 23-31, 2001.
11. Duan, Z., Feller, A. J., Toh, H. C., Makastorsis, T., and Seiden, M. V. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene (Amst.), 229: 75-81, 1999.
12. Feller, A. J., Duan, Z., Penson, R., Toh, H. C., and Seiden, M. V. TRAG-3, a novel cancer/testis antigen, is overexpressed in the majority of melanoma cell lines and malignant melanoma. Anticancer Res., 20: 4147-4151, 2000.
13. Lin, C., Mak, S., Meitner, P. A., Wolf, J. M., Bluman, E. M., Block, J. A., and Terek, R. M. Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. Gene (Amst.), 285: 269-278, 2002.
14. Chen, Z. T., Zhu, B., and Wu, Y. Z. Expression of TRAG-3 antigen in non-small-cell lung carcinomas. Lung Cancer, 38: 101-102, 2002.
15. Shieh, D. C., Lin, D. T., Yang, B. S., Kuan, H. L., and Kao. K. J. High frequency of HLA-A*0207 subtype in Chinese population. Transfusion, 36: 818-821, 1996.
16. Parker, K. C., Bendnarek, M. A., and Coligan, J. E. Scheme for ranking potential HLA-A2 binding peptides base on independent binding of individual peptide side-chains. J. Immunol., 152: 163-175, 1994.
17. Nijman, H. W., Houbiers, J. G., Vierboom, M. P., van der Burg, S. H., Drijfhout, J. W., D'Amaro, J., Kenemans, P., Melief, C. J., and Kast, W. M. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol., 23: 1215-1219, 1993.
18. Tahara, K., Takesako, K., Sette, A., Cells, E., Kitano, S., and Akiyoshi, T. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin. Cancer Res., 5: 2236-2241, 1999.
19. Martelange, V., De Smet, C., De Plaen, E., Lurquin, C., and Boon, T. Identification on a human sarcoma of two new genes with tumorspecific expression. Cancer Res., 60: 3848-3855, 2000.
20. Brasseur, F., Marchand, M., Vanwijck, R., Herin, M., Lethe, B., Chomez, P., and Boon, T. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int. J. Cancer, 52: 839-841, 1992.
21. Boel, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J. C., Coulie, P., Boon, T., and van der Bruggen, P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 2: 167-175, 1995.
22. Chen, Y. T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA, 94: 1914-1918, 1997.
23. Russo, V., Dalerba, P., Ricci, A., Bonazzi, C., Leone, B. E., Mangioni, C., Allavena, P., Bordignon, C., and Traversari, C. MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas. Int. J. Cancer, 67: 457-460, 1996.
24. de Vries, T. J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter, D. J., and van Muijen, G. N. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res., 57: 3223-3229, 1997.
25. de Vries, T. J., Trancikova, D., Ruiter, D. J., and van Muijen, G. N. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br. J. Cancer, 78: 1156-1161, 1998.
26. Castelli, C., Rivoltini, L., Andreola, G., Carrabba, M., Renkvist, N., and Parmiani, G. T-cell recognition of melanoma-associated antigens. J. Cell. Physiol., 182: 323-331, 2000.
27. Kawakami, Y., Robbins, P. F., Wang, R. F., Parkhurst, M., Kang, X., and Rosenberg, S. A. The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother., 21: 237-246, 1998.
28. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee, H. G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.), 351: 290-296, 1991.
29. Pamer. E. G., Harty, J. T., and Bevan, M. J. Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature (Lond.), 353: 852-855, 1991.
30. Rotzschke, O., Falk, K., Stevanovic, S., Jung, G., Walden, P., and Rammensee, H. G. Exact prediction of a natural T cell epitope. Eur. J. Immunol., 21: 2891-2894, 1991.
31. Celis, E., Tsai, V., Crimi, C., DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., and Serra, H. M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA, 91: 2105-2109, 1994.
32. Schirle, M., Weinschenk, T., and Stevanovic, S. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J. Immunol. Methods, 257: 1-16, 2001.
33. Celis, E., Fikes, J., Wentworth, P., Sidney, J., Southwood, S., Maewal, A., Del Guercio, M. F., Sette, A., and Livingston, B. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol. Immunol., 31: 1423-1430, 1994.
34. van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., De Smet, C., Traversari, C., Townsend, A., and Boon, T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24: 3038-3043, 1994.
35. Parkhurst, M. R., Fitzgerald, E. B., Southwood, S., Sette, A., Rosenberg, S. A., and Kawakami, Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res., 58: 4895-4901, 1998.
36. Lim, J. S., Kim, S., Lee, H. G., Lee, K. Y., Kwon, T. J., and Kim, K. Selection of peptides that bind to the HLA-A2.1 molecule by molecular modeling. Mol. Immunol., 33: 221-230, 1996.